Express Healthcare
Home  »  News  »  Healthspring receives approval to test for detecting Coronavirus Antibodies

Healthspring receives approval to test for detecting Coronavirus Antibodies

0 244
Read Article

The tests have specificity greater than 99.8 per cent, sensitivity is of 100 per cent

Healthspring has received approval from the designated authorities to start testing for detecting Coronavirus Antibodies. These tests, suited for high risk groups like immuno-compromised patients, individuals in containment zone, healthcare workers, amongst others from the essential services group; has the specificity greater than 99.8 per cent and sensitivity is of 100 per cent (14 days post-PCR confirmation). The test is a uniquely designed, high quality serology test for identification of antibodies developed in a person’s body. These antibodies indicate that the individuals may have had COVID-19 in the past and has developed antibodies that protects them from reinfection.

Commenting on the development, Kaushik Sen, Co-Founder & CEO, Healthspring, said, “We are delighted to announce that our clinics will now be conducting the antibody tests post the requisite approvals received from the authorities. These rapid antibody testing kits are of world-class standards. They are already been deployed in countries like the UK, Singapore, etc. This is a revolutionary step taken by the authorities as the results, along with other information, will help the healthcare provider make an informed recommendation about patient care. This lab-based testing process is being conducted only through NABL certified labs like Healthspring. It will be beneficial to those individuals who have been exposed to the virus or if they live in or have recently travelled to a place where transmission of COVID-19 is known to occur.”

The tests will be available at 15 clinics of Healthspring in Mumbai and Pune. Each test will charged at INR 1250*. The kit has been approved by ICMR for testing seroprevalence studies in India. The test is also CE-IVD certified and has received US FDA emergency use authorisation (EUA). There is no cross-reactivity to common cold, HIV and other coronaviruses.

*For in-centre sample collections. Additional charges applicable for onsite / home sample collections.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More